Wall Street is positive on bluebird bio Inc (BLUE). On average, analysts give bluebird bio Inc a Buy rating. The average price target is $7.421, which means analysts expect the stock to climb by 95.80% over the next twelve months. That average ranking earns bluebird bio Inc an Analyst Rating of 30, which is better than 30% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BLUE a Buy today. Find out what this means to you and get the rest of the rankings on BLUE!